Cover Image
市場調查報告書

全球乾癬治療藥市場

Global Psoriasis Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 281648
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
全球乾癬治療藥市場 Global Psoriasis Therapeutics Market 2015-2019
出版日期: 2014年12月31日 內容資訊: 英文 109 Pages
簡介

乾癬是皮膚的免疫介導性疾病,皮膚急速成長白和紅、銀的斑點。乾癬主要成人發病,不過,兒童和老年人也可見。雖然不知道原因,但是一般認為是免疫系統的過度活動引起發炎,使皮膚剝落。

本報告提供全球乾癬治療藥市場現狀與今後的預測、市場規模、各地區趨勢、主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 簡稱說明

第3章 本報告的範圍

第4章 產品簡介

第5章 市場調查方法

第6章 簡介

第7章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各作用機制市場區隔

  • INF抑制劑
  • PDE4抑制劑
  • 白細胞介素抑制劑
  • 其他

第9章 各分子類型市場區隔

  • 生技藥品
  • 小分子

第10章 各給藥途徑市場區隔

  • 口服
  • 非口服
  • 局部

第11章 各劑型市場區隔

  • 固態
  • 液體
  • 半固態

第12章 各疾病類型市場區隔

  • 輕度
  • 中度
  • 重度

第13章 各地區市場區隔

第14章 購買標準

第15章 市場成長的促進要素

第16章 促進要素與其影響

第17章 市場課題

第18章 推動市場的要素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 產品研發線

第22章 開發平台候補為目標的新機制

第23章 供應商環境

  • 競爭模式
  • 市場佔有率分析
  • 其他值得注意的供應商

第24章 主要供應商分析

  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Pfizer

第25章 本系列的其他報告

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR4943

About Psoriasis and Its Types

Psoriasis is a common immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes buildup of thick white, red, or silvery patches of skin. It alters the normal cell cycle of the skin. The new cells of the skin grow and move quickly to the surface of the skin to form patches known as "plaques". The plaques are commonly found on knees, elbows, scalp, hands, and feet. Psoriasis occurs mostly in adults, but can also be seen in children and adolescents. The etiology of the disease is unknown, however, it is believed to be an immune-mediated process. It is believed that the over-activity of the immune system can cause inflammation, thereby resulting in flaking of the skin.

TechNavio's analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 9.95 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Psoriasis Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs including systemic and topical drugs used in the treatment of:

  • Psoriasis
  • Psoriatic Arthritis

The Global Psoriasis Therapeutics market is segmented based on the mechanism of action of the drugs used to treat psoriasis and psoriatic arthritis as illustrated below:

  • TNF Inhibitors
  • PDE4 Inhibitors
  • Interleukin Blockers
  • Others

The Global Psoriasis Therapeutics market is also segmented based on the type of molecule used for the treatment of psoriasis, as illustrated below:

  • Biologics
  • Small Molecules

On the basis of route of administration adopted for the treatment of psoriasis, the Global Psoriasis Therapeutics market is segmented as follows:

  • Oral
  • Parenteral
  • Topical

The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Psoriasis Therapeutics market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of psoriasis have been discussed.

TechNavio's report, Global Psoriasis Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and the EMEA regions; it also covers the Global Psoriasis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Pfizer

Other Prominent Vendors

  • AbGenomics
  • Almirall
  • Anacor Pharmaceuticals
  • ApoPharma
  • Astellas Pharma
  • AstraZeneca
  • Aurinia Pharmaceuticals
  • Biocon
  • Biogen Idec
  • Biotest
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Celgene
  • Coherus Biosciences
  • Creabilis
  • Dermira
  • Eli Lilly
  • F. Hofffmann-La Roche
  • Forward Pharma
  • G & W Laboratories
  • GlaxoSmithKline
  • Idera Pharmaceuticals
  • Kadmon
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Maruho
  • Merck
  • Moleculin
  • MorphoSys
  • Novartis
  • Pfizer
  • Promius Pharma
  • Provectus Biopharmaceuticals
  • Sandoz
  • Sun Pharmaceuticals
  • Takeda Pharmaceutical
  • Taro Pharmaceuticals
  • Therapeutics Inc.
  • UCB
  • Valeant Pharmaceuticals
  • VBL Therapeutics

Market Driver

  • Growing Unmet Needs
  • For a full, detailed list, view our report

Market Challenge

  • Unknown Disease Etiology
  • For a full, detailed list, view our report

Market Trend

  • Market Dominance by Biologics
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Humira
    • 04.1.2. Enbrel
    • 04.1.3. Otezla
    • 04.1.4. Remicade
    • 04.1.5. Stelara

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Mechanism of Action

  • 08.1. TNF Inhibitors
  • 08.2. PDE4 Inhibitors
  • 08.3. Interleukin Blockers
  • 08.4. Others

09. Market Segmentation by Type of Molecule

  • 09.1. Biologics
  • 09.2. Small Molecules

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Market Segmentation by Dosage Form

  • 11.1. Solid
  • 11.2. Liquid
  • 11.3. Semi-solid

12. Market Segmentation by Type of Disease

  • 12.1. Mild Psoriasis
  • 12.2. Moderate Psoriasis
  • 12.3. Severe Psoriasis

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Pipeline Portfolio

22. Novel Mechanisms Targeted by Pipeline Candidates

  • 22.1. Small Molecules
    • 22.1.1. Tofacitinib
    • 22.1.2. Baricitinib
  • 22.2. Biologics
    • 22.2.1. Ixekizumab
    • 22.2.2. Secukinumab
    • 22.2.3. Brodalumab
    • 22.2.4. Tildrakizumab
    • 22.2.5. Guselkumab

23. Vendor Landscape

  • 23.1. Competitive Scenario
    • 23.1.1. Key News
    • 23.1.2. Mergers and Acquisitions
  • 23.2. Market Share Analysis 2014
    • 23.2.1. Competitive Assessment of Top Drugs for Psoriasis
    • 23.2.2. Abbvie
    • 23.2.3. Janssen Pharmaceuticals
    • 23.2.4. Amgen
    • 23.2.5. Pfizer
  • 23.3. Other and Future Prominent Vendors

24. Key Vendor Analysis

  • 20.1. Abbvie
    • 20.1.1. Key Facts
    • 20.1.2. Business Description
    • 20.1.3. Business Segmentation
    • 20.1.4. Revenue by Business Segmentation
    • 20.1.5. Revenue Comparison 2013 and 2014
    • 20.1.6. Sales by Geography
    • 22.1.7. Business Strategy
    • 22.1.8. Key Developments
    • 22.1.9. SWOT Analysis
  • 20.2. Amgen
    • 20.2.1. Key Facts
    • 20.2.2. Business Description
    • 20.2.3. Business Segmentation
    • 20.2.4. Revenue by Business Segmentation
    • 20.2.5. Revenue Comparison 2013 and 2014
    • 20.2.6. Sales by Geography
    • 20.2.7. Business Strategy
    • 20.2.8. Key Developments
    • 20.2.9. SWOT Analysis
  • 20.3. Janssen Pharmaceuticals
    • 20.3.1. Key Facts
    • 20.3.2. Business Description
    • 20.3.3. Business Segmentation
    • 20.3.4. Revenue by Business Segmentation
    • 20.3.5. Revenue Comparison 2013 and 2014
    • 20.3.6. Sales by Geography
    • 20.3.7. Business Strategy
    • 20.3.8. Key Developments
    • 20.3.9. SWOT Analysis
  • 20.4. Pfizer
    • 20.4.1. Key Facts
    • 20.4.2. Business Description
    • 20.4.3. Business Segmentation
    • 20.4.4. Revenue by Business Segmentation
    • 20.4.5. Revenue Comparison 2013 and 2014
    • 20.4.6. Sales by Geography
    • 20.4.7. Business Strategy
    • 20.4.8. Key Developments
    • 20.4.9. SWOT Analysis

25. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot of the Global Psoriasis Therapeutics Market
  • Exhibit 3: Global Psoriasis Therapeutics Market 2014-2019 (US$ million)
  • Exhibit 4: Drivers and Challenges of Global Psoriasis Therapeutics Market
  • Exhibit 5: Global Psoriasis Therapeutics Market Segmentation by Mechanism of Action
  • Exhibit 6: Global Psoriasis Therapeutics Market Segmentation by Mechanism of Action 2014
  • Exhibit 7: Global Psoriasis Therapeutics Market Segmentation by Type of Molecule
  • Exhibit 8: Global Psoriasis Therapeutics Market Segmentation by Type of Molecule 2014
  • Exhibit 9: Global Psoriasis Therapeutics Market Segmentation by Route of Administration
  • Exhibit 10: Global Psoriasis Therapeutics Market Segmentation by Route of Administration 2014
  • Exhibit 11: Global Psoriasis Therapeutics Market Segmentation by Dosage Form
  • Exhibit 12: Global Psoriasis Therapeutics Market Segmentation by Route of Administration 2014
  • Exhibit 13: Global Psoriasis Therapeutics Market Segmentation by Type of Disease
  • Exhibit 14: Global Psoriasis Therapeutics Market Segmentation by Type of Disease 2014
  • Exhibit 15: Global Psoriasis Therapeutics Market by Geographical Segmentation 2014
  • Exhibit 16: Buying Criteria of the Global Psoriasis Therapeutics Market
  • Exhibit 17: Drivers and Their Impact on the Key Customer Category of the Global Psoriasis Therapeutics Market
  • Exhibit 18: Drivers and Their Geography-wise Impact on the Global Psoriasis Therapeutics Market
  • Exhibit 19: Phase III Pipeline Molecules for Psoriasis
  • Exhibit 20: Percentage Comparison of Pipeline Molecules for Psoriasis Treatment
  • Exhibit 21: Novel Targets of the Pipeline Candidates
  • Exhibit 22: Candidates Under Development: Tofacitinib
  • Exhibit 23: Candidates Under Development: Baricitinib
  • Exhibit 24: Candidates Under Development: Ixekizumab
  • Exhibit 25: Candidates Under Development: Sekukinumab
  • Exhibit 26: Candidates Under Development: Brodalumab
  • Exhibit 27: Candidates Under Development: Tildrakizumab
  • Exhibit 28: Candidates Under Development: Guselkumab
  • Exhibit 29: YoY Sales Comparison of Top Drugs for Psoriasis 2010-2013 (US$ million)
  • Exhibit 30: Revenue Share of the Top Drugs for Psoriasis 2011-2013
  • Exhibit 31: YoY Global Sales of Humira 2008-2013
  • Exhibit 32: YoY Global Sales of Remicade 2005-2013
  • Exhibit 33: YoY Global Sales of Stelara 2005-2013
  • Exhibit 34: YoY Sales of Enbrel (In US and Canada) 2005-2013
  • Exhibit 35: YoY Sales of Enbrel In US 2005-2013
  • Exhibit 36: YoY Sales of Enbrel In Canada 2005-2013
  • Exhibit 37: Region-wise Sales Comparison of Enbrel 2005-2013
  • Exhibit 38: YoY Sales of Enbrel (Outside US and Canada) 2009-2013
  • Exhibit 39: Abbvie: Business Segmentation 2014
  • Exhibit 40: Abbvie: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 41: Abbvie: Sales by Geography (in US$ million)
  • Exhibit 42: Amgen: Business Segmentation by Revenue 2013 and 2014
  • Exhibit 43: Amgen: Sales by Geography 2014 (Pharmaceuticals Division)
  • Exhibit 44: Amgen: Sales by Geography 2014 (Diagnostics Division)
  • Exhibit 45: Janssen: Business Segmentation by Revenue 2014
  • Exhibit 46: Janssen: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 47: Janssen: Sales by Geography 2014
  • Exhibit 48: Pfizer: Business Segmentation
  • Exhibit 49: Pfizer: Revenue by Business Segmentation 2014
  • Exhibit 50: Pfizer: Revenue by Business Segmentation 2013 and 2014 (US$ million)
  • Exhibit 51: Pfizer: Revenue by Geographical Segmentation 2014
Back to Top